Contineum Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CTNM research report →
About the company
Contineum Therapeutics, Inc. , a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
- CEO
- Carmine N. Stengone
- IPO
- 2024
- Employees
- 51
- HQ
- San Diego, CA, US
Price Chart
- Market Cap
- $564.53M
- P/E
- -7.74
- P/S
- 0.00
- P/B
- 2.25
- EV/EBITDA
- -9.49
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -27.09%
- ROIC
- -26.01%
- Revenue
- $0 · 0.00%
- Net Income
- $-59,978,000 · -41.93%
- EPS
- $-2.17 · -33.13%
- Op Income
- $-68,059,000
- FCF YoY
- -66.50%
- 52W High
- $16.91
- 52W Low
- $3.72
- 50D MA
- $13.18
- 200D MA
- $12.60
- Beta
- 0.89
- Avg Volume
- 306.99K
Get TickerSpark's AI analysis on CTNM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 30, 26 | Lorrain Daniel S. | other | 28,826 |
| Jul 1, 26 | Lorrain Daniel S. | other | 4,183 |
| Jun 30, 26 | Lorrain Daniel S. | sell | 28,826 |
| Jul 1, 26 | Lorrain Daniel S. | sell | 5,852 |
| Jul 1, 26 | Lorrain Daniel S. | sell | 2,501 |
| Jun 30, 26 | Lorrain Daniel S. | other | 28,826 |
| Jul 1, 26 | Lorrain Daniel S. | other | 4,183 |
| Jun 30, 26 | Watkins Tim | other | 10,833 |
| Jun 30, 26 | Watkins Tim | other | 10,833 |
| Jun 30, 26 | Watkins Tim | sell | 10,833 |
Our CTNM coverage
Recent articles, reports, and earnings notes.
No research on CTNM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CTNM report →Similar companies
Peers in the same neighborhood.